Quick Answer
RELMADA THERAPEUTICS, INC. reported Cash and Equivalents of $3.50 million for fiscal year 2025.
RELMADA THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.50M | -9.3% |
| 2024 | $3.86M | -5.7% |
| 2023 | $4.09M | -24.2% |
| 2022 | $5.40M | -87.9% |
| 2021 | $44.44M | +1681.0% |
| 2020 | $2.50M | -93.1% |
| 2019 | $36.28M | +293.6% |
| 2019 | $9.22M | +279.8% |
| 2018 | $2.43M | +8.4% |
| 2018 | $2.24M | +30.9% |
| 2017 | $1.71M | -79.9% |
| 2016 | $8.50M | -62.2% |
| 2015 | $22.47M | -12.1% |
| 2014 | $25.56M | +625.8% |
| 2013 | $3.52M | +98.7% |
| 2012 | $1.77M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.38M | -6.7% | +2.3% |
| June 30, 2025 | $1.35M | -35.1% | +17.7% |
| March 31, 2025 | $1.15M | -13.9% | -70.2% |
| December 31, 2024 | $3.86M | -5.7% | +159.9% |
| September 30, 2024 | $1.48M | -77.8% | -28.9% |
| June 30, 2024 | $2.09M | -85.6% | +56.3% |
| March 31, 2024 | $1.34M | -95.4% | -67.4% |
| December 31, 2023 | $4.09M | -24.2% | -38.9% |
- RELMADA THERAPEUTICS, INC. showed a decrease of -9.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, RELMADA THERAPEUTICS, INC.’s cash and equivalents has grown by 97.2% (from $1.77 million to $3.50 million).
- The most recent figure is from RELMADA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: